Halozyme Therapeutics (HALO) PT Raised to $56 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Do Kim raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $56.00 (from $47.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
